Dopamine (DA) availability for precursor function and peripheral biological action is dependent on synthesis and inactivation enzymes, most of them have been cloned and located. An aromatic acid decarboxylase (AADC) defect has been reported in male homozygotic twins. The syndrome of complete dopamine-i9-hydroxylase deficiency with orthostatic hypotension and very high DA contributes to our understanding of the role of DA as a catecholamine with a peripheral biological action of its own. Xlinked isolated monoamine oxidase A gene deficiency represents a marked disturbance of monoamine metabolism. The genes of the two major extraneuronal DA-metabolizing enzymes -catechol-O-methyltransferase and phenolsulfotransferase (PST) -have also been defined. Of particular interest is a bidirectional shuttle system between the PST and sulfatase which have been cloned and located. DA, highly sulfoconjugated via PST, yields DA sulfate which is reconvertible by sulfatase to free DA. A defect of sulfatase catalyzing this process results in a predominance of DA as biologically inactive DA sulfate and so attenuates the DA action. Enzymatic defects of DA synthesis and metabolism are thus genetic modulators of DA action. (Hypertens Res 1995; 18 Suppl. I: S1-S10)
Major advances in the molecular biology of genes determining catecholamine synthesis, metabolism and action have led to the cloning and chromosome location of virtually all major enzymes, transporters and receptors that influence the genetic impact on eventual catecholamine effects (for review see 1) . Interindividual variations of the main plasma catecholamines in studies of twins have shown that the genetic dependence of dopamine (DA) is particularly high [72% compared with 57% for norepinephrine (NE)] while the environmental impact on DA and NE variability is comparable at a lower 27-28% level (2) . The determinants of DA action, additional to DA release and inactivation, i. e. the genes of multiple DA receptors, have also been impressively explored. Their expression in the brain and other tissues, particularly the kidney, has led to the recognition of a potential DA receptor defect in experimental hypertension (3) .
This overview focuses on pre-receptor aspects of the genetic determinants of DA availability, i.e. the cloning and location of enzymes involved in DA synthesis and inactivation. Dopamine-R-hydroxylase (Dj9H), which catalyzes DA conversion to NE, and two major enzymes controlling the degradative pathways for DA -catechol-0-methyltransferase ( COMT) and monoamine oxidase (MAO) -have been shown, in both twin (4) and familial aggregation studies (5) , to be almost entirely genetically determined. These enzymes (Table 1) represent crucial determinants of the ratio between DA and NE which affects the hormonal and cardiovascular balance and, indirectly, blood pressure (BP) regulation (Fig. 1) .
3,4-Dihydroxyphenylalanine (DOPA) decarboxylation by the action of aromatic acid decarboxylase (AADC) is a widely distributed process mostly responsible for DA synthesis in peripheral organs, particularly the kidney. The syndrome of AADC deficiency (6) is associated with an excess of some AADC substrates (such as DOPA, 3-methoxytyrosine, 5-OH-tryptophan) and there is a defect of decarboxylation products (DA and, indirectly, NE and serotonin). The abnormalities found in apparently heterozygote parents of affected children (born from a marriage of two cousins) are intermediate between the affected children and control subjects (Fig. 2) . Clinically, the condition is characterized by abnormal eye and limb movements, excessive sweating, hypotension, temperature instability, cerebral atrophy and hyponatremia. It can be partially improved by combination of a DA agonist, bromocriptine, and pyridoxine, a cofactor of AADC.
The well identified and mapped gene for DJ3H, a copper-containing glycoprotein, represents a crucial biosynthetic junction, the main determinant of the DA:NE ratio. Complete DJ9H deficiency is a rare condition with low NE and epinephrine (E) levels and increased DA concentrations in blood and cerebrospinal fluid (7) . Clinically, it is the clearest known abnormality of DANE balance tilted to-wards DA and resulting in severe orthostatic hypetension, spontaneous hypoglycemia, ptosis of the eyelids, well described in less than 10 patients up to now. However, intellectual, parasympathetic and sympathetic cholinergic functions are normal. The D/9H defects may also be partial in familial dysautonomia (8), relative when D/9H becomes temporarily rate-limiting (9), or secondary to another genetic anomaly such as Menkes (kinky hair) disease, a genetic copper transport deficiency resulting in decreased copper, a coenzyme of DI9H (10). Of wider practical interest is the relative D/9H d eficiency expressed in stress-induced distorted sympathetic activation (9) cumulating in a DA discharge exceeding that of NE and E. Such a discharge can be observed in some forms of hyperadrenergic paroxysmal hypertension (11). In addition, physiological adaptation with a DA discharge exceeding that of NE (unpublished data to be reported) has been pinpointed in a condition known as idiopathic hypovolemia (12). It is not clear whether decreased D/9H activity is due to DI9H gene expression diminished by increased sympathetic tone which characterizes this and similar clinical conditions. Alternatively, temporary activation of tyrosine hydroxylase (TH) by stress exceeding D/9H activation (9) may be responsible.
The genetic control of DA reuptake and metabo- Recently, an even more specific mutation in the 8 exon of the MAO A structural gene was identified in a large Dutch kindred with several males affected by a syndrome of borderline mental retardation and abnormally aggressive, violent and impulsive behaviour (arson, rape, exhibitionism, suicide) while obligate female carriers in their family had normal intelligence and behaviour (17). In both Norrie's disease (16) and the MAO A gene mutation (17), the most prominent features of catecholamine excretion are decreased elimination of totally or partially MAO-dependent metabolites such as methoxy-hydroxy-phenylglycol (MHPG), vanillyl mandelic acid (VMA) and homovanillic acid (HVA) while 0-methylated metabolites (normetanephrine, dopacetic acid or DOPAC, 3-methoxytyramine) are compensatorily elevated (Fig. 3) .
The COMT gene has been cloned and located (18). Although genetic variations of COMT have been well characterized in twin studies (4), there is not yet a specific clinical disorder attributed to COMT gene deficiency. One possible clinical COMT deficiency syndrome reflecting the genetic polymorphism regulating COMT activity in red blood cells, kidney, lung and lymphocytes is low "methylator status" (19) responsible for individual anomalies in the metabolism of some catechol drugs (L-DOPA, isoproterenol, a-methyl-dopa).
The cloning and genetic characterization of the sulfoconjugating enzyme phenyl sulfotransferase (PST) (20) and deconjugating enzyme sulfatase (21) I (1995) have put this inactivation or rather intermediate metabolic system of catecholamines into new perspective. This system has two particular features:
1) The sulfoconjugation-deconjugation process is apparently different for individual catecholamines and organs.
2) The bidirectional character of the sulfoconjugation-deconjugation process suggests its reversibility with catecholamine sulfates becoming possible alternative sources of free catecholamines.
1. The degree of and dependence on sulfoconjugation are very different for individual catecholamines. This results in different concentrations of circulating conjugated catecholamines. The highest dependence on DA sulfoconjugation is reflected by an average 97% fraction of total DA circulating in conjugated form with DA having the highest affinity for platelet PST activity. The lowest degree of sulfoconjugation is that of NE (73% of total circulating NE) with a correspondingly low affinity for PST. E occupies an intermediate position (84% of total circulating E) (22) ( Table 2 ). Even at one end of this spectrum, the difference is apparent when similar doses of DA or E are infused and the very high degree of DA conversion to DA sulfate and slow conversion of E to E sulfate are compared (23). Sulfoconjugation velocities reflect the dependence of individual catecholamines on conjugation from the low estimated, when all other inactivation pathways are blocked (24) , to be around 24% for NE to the yet unknown but considerably higher proportion of DA. The proportion of DA inactivated by sulfoconjugation in man can be estimated from studies indicating that, 3 h after free DA infusion, DA sulfate concentrations exceed those of DOPAC and HVA, two principal alternative DA metabolites measurable in plasma (23).
The deconjugation process of individual catecholamines appears to be dependent on the organ in which it occurs. This is an indirect measure of sulfatase content in these organs. The deconjugation product of DA sulfate yielding free DA in the dog, the species closest to man in sulfoconjugation, is highest in the kidney, descending in order in the liver, intestine and heart (25) . Catecholamine sulfates are hydrolyzed by human arylsulfatases A, B and C in vitro with Km in the millimolar range (26) . Arylsulfatase A is the most important sulfatase present in most human tissues. This enzyme preferentially deconjugates the 4-sulfate isomer of DA (27) , leaving the 3-sulfate isomer of DA as the main circulating form of DA sulfate in man (28) . DA-4-sulfate deconjugation has also been demonstrated in the perfused rat right atrium in vivo (29) .
2. The bidirectional character of sulfoconjugation and deconjugation is best illustrated by DA, the most conjugated catecholamine (Fig. 4) . The highest degree of DA conjugation results in very low plasma free DA, at the limit of detection, while DA sulfate corresponds to the almost entire DA content circulating in plasma (23). Compared to the very short half-life of free DA (2-3 min) the long halflife DA sulfate (2-3 h), to which free DA is rapidly converted, makes it, besides free DA, an excellent alternative marker of free DA release. Physiological studies of free and sulfated catecholamines during the diurnal rhythm (30), exercise (31) and stress (32) indicate a reciprocal relationship between free and conjugated catecholamine changes. This suggests that physiological stimulation can activate a reverse process in which conjugated catecholamines become a source of free catecholamines in addition to their neuronal or paracrine release. During the diurnal rhythm, exercise and stress, glucocorticoids moving in the same direction as free catecholamines but opposite to conjugated catecholamines may be a stimulus of arylsulfatase activation, as suggested by some experimental data (33) . In man, the essential There are some indications of interindividual differences in the rapidity of sulfoconjugation in randomly-selected control subjects reacting to DA infusion as fast and slow conjugators (23,34). After a borderline hypertensive DA infusion (4 ,ug/kg/min), slow conjugators present a BP response with more free DA remaining to be converted to NE than fast conjugators who show no BP response and no change in free NE. Since this is reproducible in the same individuals (34), genetics apparently modulate sulfoconjugation patterns. It is not evident whether genetic location is on the PST or sulfatase site. Although measurements of platelet PST activity do not show any difference between slow and fast conjugators (34), it is not yet clear to what degree platelet PST activity is reflected in other tissues, despite a good correlation between platelet and tissue PST activities (5). Alternative compensatory sulfoconjugation may occur, as seen in platelet deficiency states in which is normal catecholamine sulfoconjugation (35) . Much less is known about the genetics of arylsulfatase A in man.
Potential BP Regulation Via Genes Involved in Catecholamine Synthesis and Metabolism
As is apparent from Fig. 1 , the ratio between DA and NE is an important BP determinant. A high DANE ratio is clearly related to hypotension in the congenital DJ3H deficiency syndrome (7) ( Table 3) .
That DA itself, at least in concentrations found in this syndrome, has a hypotensive action is demonstrated by the finding that TH inhibition by amethyl paratyrosine, resulting in decreased urinary DA excretion (with no change in almost undetectable NE), induces an increase of BP (36) . The mechanism of hypotension in congenital AADC deficiency is more controversial (6). It is not clear which of the elevated AADC substrates (DOPA, 3-methoxytyrosine, 5-OH-tryptophan) or decreased products (DA, NE, serotonin) or their imbalance may contribute to hypotension. In the relationship between genetics and orthostatic intolerance (37), idiopathic hypovolemia (12) is one form which may be somehow associated with excess DA. Among 14 patients with an average 32% unexplained decrease of plasma volume, we observed that orthostatism -accentuated hypovolemia and sympathetic discharge (tachycardia, palpitations) without excess NE -was accompanied by excess DA in 10 subjects, as determined by DA sulfate. It is conceivable that a partially inborn DA excess (such as an incomplete DISH defect), results in an exaggerated natriuretic DA effect and a vicious circle type of abnormality, further perpetuating the otherwise unexplained hypovolemia. Such an excess may escape attention without DA sulfate determinations since free DA remains low. This was also the case in a random series of patients with orthostatic hypotension of several etiologies where DA sulfate hyperresponsiveness to posture distinguished them from control subjects (38) .
The hypotension in Norrie's disease (16) with MAO A and B defects is not clearly understood. It may not be necessarily due to MAO deficiency. In the deleted part of the X-chromosome, other genes may also be concomitantly deleted. Despite these uncertainties, undoubtedly genetic abnormalities, even incomplete, may result in hypotensive phenotypes.
A review of several studies by Bell (39) has shown that patients with essential hypertension have a significantly lower plasma DANE ratio than control subjects. A relationship to genetics via altered DANE balance may be mediated, because an overwhelming role of reuptake in inactivation, by defects in NE and DA reuptake via respective transporters. Such a mechanism would, however, be more important in the periphery for NE than for DA. Moderately reduced DA generation from DOPA in stable hypertension (40) and borderline decreased plasma AADC concentrations in hypertension (41) may also indicate a partial genetic defect in AADC, which can be overcompensated by a feedback TH stimulation-induced NE increase. There is no evidence yet that a COMT gene defect could result in a disparity between NE and DA methylation and consequently in the DA:NE ratio. However, increased urinary DOPAC excretion in hypertension following DOPA administration (40) could emanate from excessive intraneuronal DA metabolism compensatory to a partial COMT defect.
A potential MAO B defect in hypertension has been suggested by lower MAO B activity in platelets of hypertensive patients (42) , but its role is still not clear. The practical importance of a MAO B defect, even if it is partial, may consist of a genetic counterpoint to consequences of pharmacological MAO inhibition: increased sensitivity to food containing some NE-releasing substances (such as tyramine), to phenylpropanolamine-containing drugs used as nasal decongestants, stimulants and appetite suppressants or to catecholamine reuptake inhibitors such as cocaine, which may all cause catecholamine-induced cardiovascular abnormalities such as hypertensive crises or arrythmia (4, 5) . Most recently, elevated plasma DA sulfate (but not NE and E sulfate or free DA) concentrations were found to be a marker of cocaine addicts (43).
An abnormality of the PST-sulfatase shuttle in essential hypertension is suggested by the finding that the low free DANE ratio previously observed in hypertension (39) is associated with the opposite in the ratio of sulfoconjugates: a higher DA sulfate/NE + E sulfate ratio with an absolute increase in plasma DA sulfate and decreased NE + E sulfate (44) (Fig. 5) . Such a reversed ratio of catecholamine sulfates itself may mirror the decreased free DANE ratio with predominating high affinity DA sulfoconjugation at the expense of NE thus decreased residual free DA:NE ratio. The initially-described high plasma DA sulfate levels in hypertension (44), confirmed and specified to be DA 3-0-sulfate (28), indicate virtually entire sequestration of antihypertensive DA in biologically inactive DA sulfate form while lower affinity NE and E sulfoconjugation tend to increase the concentrations of prohypertensive free NE and E. This probably characterizes the established form of hypertension when free DA becomes disproportionally low in comparison to NE (45) .
These DA patterns are, however, not universal for all stages of hypertension. Normotensive relatives of hypertensive patients tend to have lower DA excretion (46) in the presence of increased NE spillover (47) . When hypertension initially develops and becomes borderline, urinary DA is found to remain decreased in some cases (48) while DA indices such as HVA (49) or urinary DA increase in others (45, 50) . The DA increase may initially represent a defense reaction to heightened sympathetic tone (45) in which indices of DA exocytosis rise (51) and the higher DA levels oppose the biological actions of NE (vasoconstriction, antinatriuresis, etc.). Only when hypertension becomes established does free DA decrease (45) , and this particularly affects elderly subjects (52) , black patients (53) as well as some forms of hypertension such as salt-sensitive hypertension (54) , low renin hypertension (55) , and hypertension in diabetics (56) . During these evolutionary patterns of hypertension, homeostatic responses modulated by the genetic background of each individual probably determine the eventual impact of the abnormality. (42, 44) . With uncertainty over whether platelet PST activity is a marker of overall sulfoconjugating activities, circumstantial evidence indicates that the DA sulfate excess in unselected hypertensive subjects may be due to a sulfatase defect. Such a defect may be wider, as suggested in hypertension by increased sulfates of dehydroepiandrosterone (DHEA), a steroid similar to DA in its precursor function with weak biological activity and a high degree of sulfoconjugation (57) , most comparable with the functions and conjugation patterns of DA. The close homology of steroid sulfatase and arylsulfatase A, both located on chromosome 22 (21), raises the possibility that increased plasma DA sulfate (28, 44) and DHEA sulfate (58) (with both undergoing decreased renal excretion) in essential hypertension (28, 58) may be related to a common defect in the sulfatase gene family. Such a defect, with the predominant kidney location of sulfatase (25) may, moreover contribute to the decreased renal clearance of two DA sulfate isomers in patients with essential hypertension (28) and to their elevated plasma DA sulfate levels.
In the presence of such overall patterns in unselected essential hypertension patients, there are probably subgroups in which a partial PST deficiency may predominate. This may be the case in pseudopheochromocytoma patients with defective NE and E conjugation as well as free NE and E responses to stimulation higher than those seen in control subjects (59) . On the other hand, clinically comparable patients at the same time, often have DA discharges, particularly in the sulfated form (11). It may thus be no accident that, under those circumstances, there is a significant positive relationship between plasma free NE and DA sulfate (3-DA-O-sulfate) in essential hypertension (28) . Conceivably, a change in the sulfoconjugation balance favoring DA at the expense of NE and E and leaving more free NE (Fig. 6 ) may be due to decreased PST gene expression, but still sufficient to accommodate high affinity DA sulfoconjugation at the expense of low affinity NE and E conjugation. It is not clear whether this may be a consequence of increased sympathetic tone which characterizes this form of hyperadrenergic hypertension (59) . It will be important to distinguish to what degree this sulfoconjugation imbalance is one of the factors additional to increased NE spillover in this form of hypertension (60) , permitting NE action unopposed by DA which is sequestrated as an inactive metabolite (DA sulfate). There are other conditionssuch as congestive heart failure -in which the dynamics of free and conjugated DA changes suggest that both are interconvertible, and conjugated DA serves as a reservoir of active DA, thus becoming a sulfatase-dependent modulator of free DA availability (61) .
Eventually, some genetic abnormalities, such as mutation of the MAO A gene (17), may not necessarily result in anormalies of the DA: NE ratio and of BP regulation.
These findings represent an initial step in our understanding of how some inborn determinants of DA synthesis and metabolism modulate the final biological impact of DA. Genetic polymorphism may explain ethnic differences in urinary DA output by normotensive adults from several ethnic groups (62) and possibly also some gender difference with higher urinary DA excretion in women than in men (63) . It is not clear whether such differences reside Fig. 5 . Plasma conjugated DA, conjugated NE + E and % conjugated NE + E in 24 control subjects and 59 unselected patients with essential hypertension (data from refs. 44 and 59) . Baseline values in patients with labile episodic hypertension are indicated by • . Despite statistical differences, a wider spread and overlapping with controls are apparent in essential hypertension. The conjugated DAINE + E ratio is elevated in hypertensive patients compared to controls (3.9 ± 1.2 vs. 0.9 ± 0.3, p < 0.02). The % of DA sulfates as a proportion of total plasma DA (not indicated) remains comparably high (97-99%) but that o f NE + E sulfates is significantly lower. Patients with episodic hypertension have the highest baseline DA sulfate values, lowest NE + E sulfates and a clearly lower percentage of NE + E sulfoconjugation.
in sex-dependent genetic enzymatic variations or whether PST activity very specific to DA is inhibited by estrogens (64) , thus leaving more free DA. Genetic differences may also be responsible for some alterations in dopaminergic functions, such as anomalous responsiveness of aldosterone to posture and metoclopramide in Japanese patients compared to Caucasians both with aldosterone-producing adenomas (65) .
It is probably the impact of several biosynthetic and metabolic steps on the DA: NE ratio which mediates BP-decreasing or increasing effects of the respective genes. Genetic modulation of that unique system of both metabolism and potential reverse synthesis of catecholamines, the conjugation-deconjugation shuttle as we know it, has become particularly interesting, thatiks to cloning of the respective enzymes. Complete enzymatic defects, even if extremely rare, serve as models for understanding the mechanism(s) by which such genetic defects effect cardiovascular abnormalities.
Partial defects or mutations may further advance our understanding of how the underlying genome interacts with environmental changes in the genesis of cardiovascular diseases such as hypertension.
